Capasso Planning Partners Trims Stake in Eli Lilly

Institutional investor reduces holding in pharmaceutical giant by over 40%

Published on Mar. 6, 2026

Got story updates? Submit your updates here. ›

Capasso Planning Partners LLC, an investment management firm, has reduced its stake in Eli Lilly and Company (NYSE:LLY) by 43.3% during the third quarter, according to a recent SEC filing. The firm now holds 810 shares of the pharmaceutical company's stock, down from 1,429 shares previously.

Why it matters

Eli Lilly is one of the world's largest pharmaceutical companies, known for developing innovative drugs across a range of therapeutic areas. Changes in institutional ownership of Lilly's stock can provide insights into market sentiment and expectations around the company's future performance.

The details

According to the filing, Capasso Planning Partners sold 619 shares of Eli Lilly stock during the third quarter. The firm's remaining 810 shares were valued at $618,000 as of the most recent SEC reporting period. Capasso Planning Partners is one of many institutional investors and hedge funds that have adjusted their positions in Eli Lilly in recent quarters.

  • Capasso Planning Partners reduced its Eli Lilly stake during the third quarter of 2026.

The players

Capasso Planning Partners LLC

An investment management firm that has reduced its holdings in pharmaceutical giant Eli Lilly and Company.

Eli Lilly and Company

A global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana, known for developing innovative drugs across a range of therapeutic areas.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Capasso Planning Partners' Eli Lilly stake reflects broader market trends and investor sentiment around the pharmaceutical industry. While Lilly remains a dominant player, changes in institutional ownership can signal evolving expectations around the company's future growth and performance.